<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03335618</url>
  </required_header>
  <id_info>
    <org_study_id>16-20505</org_study_id>
    <nct_id>NCT03335618</nct_id>
  </id_info>
  <brief_title>Coaching and Activity Tracking in Multiple Sclerosis - A Pilot Study</brief_title>
  <acronym>CoachMS</acronym>
  <official_title>A First-in-Kind Randomized, Controlled Pilot Clinical Trial Testing Proactive vs Reactive Management of a Symptom Triad in Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this 12-week, exploratory pilot clinical trial is to continuously and remotely
      assess a triad of bothersome multiple sclerosis (MS) symptoms (BAM: bladder, ambulation,
      mood) and test the benefit of proactively treating these symptoms according to an
      evidence-based, multi-disciplinary, personalized protocol.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      MS is a chronic, debilitating disease of the central nervous system affecting approximately 2
      million people worldwide and more than 400,000 individuals in the US. MS is the most common
      cause of non-traumatic neurological disability in young adults. Symptoms typically first
      afflict individuals during the prime of their professional and reproductive lives, between
      the ages of 20 and 40. Many affected individuals are unemployed, physically disabled, and at
      high risk for social isolation. While disease-modifying therapies (DMTs) can significantly
      reduce accumulation of disability in MS, patients still experience symptoms across a range of
      functional domains. Symptoms can include problems with bladder, walking, and mood (depression
      and anxiety). Often, these symptoms are only partially evaluated during routine MS clinic
      visits, and the long interval between clinic visits can result in them not being optimally
      managed.

      The goal of the current study is to pilot a system of proactively monitoring a combination of
      symptoms (bladder, ambulation and mood) using an activity monitor and a smartphone.

      Adult patients with MS who are experiencing symptoms in at least 2 of the 3 domains (bladder,
      ambulation, mood) will be enrolled. Visits will be at baseline (can be same day as routine
      visit to the MS clinic), and 3 months. Short surveys (&lt;3 minutes to complete) will occur
      weekly, and longer surveys will occur at baseline, 6 weeks and 3 months. FitBit activity
      monitors will be worn for the entire 3 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2017</start_date>
  <completion_date type="Anticipated">December 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of an active symptom monitoring and intervention protocol</measure>
    <time_frame>12 weeks</time_frame>
    <description>To evaluate feasibility of the intervention, we will calculate how many patients remain in the study, levels of patient satisfaction with the monitoring and intervention, and we will analyze patient and provider feedback.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in ambulation symptoms in MS participants</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in average daily step count according to FitBit step tracking. We will assess the mean observed change of daily steps between both the actively monitored group and the passively monitored group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in mood symptoms in MS participants.</measure>
    <time_frame>12 weeks</time_frame>
    <description>We will measure changes in the Center of Epidemiologic Studies Depression Scale-Revised (CES-D-R), which is a patient questionnaire that provides a measure of depression. It consists of 20 questions, each of which receives a score between 0 and 3, with higher scores indicating worse depression. The total CESD-R score (0-60) also permits categorization of no, mild, moderate and severe depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in bladder symptoms in MS participants.</measure>
    <time_frame>12 weeks</time_frame>
    <description>At the end of the study, we will measure change in the Actionable Bladder Symptom Screening Tool (ABSST), which is a patient-reported scale that identifies patients who could benefit from lower urinary tract assessment and/or possibly treatment. It consists of 8 questions, each graded on 4 points, with higher scores indicating worse bladder function.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Active Coaching and Monitoring</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Passive Monitoring</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Activity Monitoring and Symptom Coaching</intervention_name>
    <description>Triggered check-ins by study personnel to keep participants on track to meet fitness goals</description>
    <arm_group_label>Active Coaching and Monitoring</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Passive Activity Monitoring</intervention_name>
    <description>Passive step tracking without check-ins</description>
    <arm_group_label>Passive Monitoring</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any individual above the age of 18 with a confirmed diagnosis of MS

          -  Access to a smartphone

          -  Access to Wi-Fi at home

          -  Able to walk (including with a cane or walker)

          -  Willing to fill out surveys at multiple time points

        Exclusion Criteria:

          -  Clinician's assessment of cognitive, dexterity, or visual impairment limiting ability
             to use a smartphone and subsequent technologies required by the study

          -  Inability to walk
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Riley M Bove, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Riley M Bove, MD</last_name>
    <phone>(415) 353-2069</phone>
    <email>riley.bove@ucsf.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Bove R, Garcha P, Bevan C, et al. Towards a Tele-MSDS: an iterative method to assess the MS patient remotely. ECTRIMS. London 2016.</citation>
  </reference>
  <reference>
    <citation>Ritvo PG F, J. S., Miller, D. M., Andrews, H., Paty, D. W., LaRocca, N.G. . Multiple Sclerosis Quality of Life Inventory: A User's Manual. New York: National Multiple Sclerosis Society, 1997.</citation>
  </reference>
  <reference>
    <citation>Schwartz CE, Ayandeh A, Motl RW. Investigating the minimal important difference in ambulation in multiple sclerosis: a disconnect between performance-based and patient-reported outcomes? J Neurol Sci. 2014 Dec 15;347(1-2):268-74. doi: 10.1016/j.jns.2014.10.021. Epub 2014 Oct 18.</citation>
    <PMID>25455299</PMID>
  </reference>
  <reference>
    <citation>Motl RW, Pilutti L, Sandroff BM, Dlugonski D, Sosnoff JJ, Pula JH. Accelerometry as a measure of walking behavior in multiple sclerosis. Acta Neurol Scand. 2013 Jun;127(6):384-90. doi: 10.1111/ane.12036. Epub 2012 Dec 13.</citation>
    <PMID>23240822</PMID>
  </reference>
  <reference>
    <citation>Bove R, White CC, Giovannoni G, Glanz B, Golubchikov V, Hujol J, Jennings C, Langdon D, Lee M, Legedza A, Paskavitz J, Prasad S, Richert J, Robbins A, Roberts S, Weiner H, Ramachandran R, Botfield M, De Jager PL. Evaluating more naturalistic outcome measures: A 1-year smartphone study in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2015 Oct 15;2(6):e162. doi: 10.1212/NXI.0000000000000162. eCollection 2015 Dec.</citation>
    <PMID>26516627</PMID>
  </reference>
  <reference>
    <citation>Block VJ, Liz√©e A, Crabtree-Hartman E, Bevan CJ, Graves JS, Bove R, Green AJ, Nourbakhsh B, Tremblay M, Gourraud PA, Ng MY, Pletcher MJ, Olgin JE, Marcus GM, Allen DD, Cree BA, Gelfand JM. Continuous daily assessment of multiple sclerosis disability using remote step count monitoring. J Neurol. 2017 Feb;264(2):316-326. doi: 10.1007/s00415-016-8334-6. Epub 2016 Nov 28.</citation>
    <PMID>27896433</PMID>
  </reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 19, 2017</study_first_submitted>
  <study_first_submitted_qc>November 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2017</study_first_posted>
  <last_update_submitted>November 3, 2017</last_update_submitted>
  <last_update_submitted_qc>November 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Riley Bove, MD</investigator_full_name>
    <investigator_title>Associate Professor of Clinical Neurology</investigator_title>
  </responsible_party>
  <keyword>Activity</keyword>
  <keyword>Mood</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

